what is treatment-naive

by Joyce Luettgen Published 2 years ago Updated 2 years ago

A person is considered to be treatment naive if they have never undergone treatment for a particular illness. In the world of sexually transmitted infections, the term is most often used to refer to people who are HIV-positive and who have never taken any antiretroviral therapy for their infection.

A person is considered to be "treatment-naive" if they have never undergone treatment for a particular illness. 1 In the world of sexually transmitted infections (STIs), the term is most often used to refer to people who are HIV-positive and who have never taken any antiretroviral therapy for their infection.Feb 15, 2022

Full Answer

What is treatment naive for illness therapy?

Apr 10, 2006 · Answer. "Treatment naive" means you have never been treated before with antiretroviral therapy. Every patient with HIV infection is …

What does treatment naive mean in STDs?

Treatment-Naive HIV/AIDS Glossary. Glossary search. Glossary search. Apply. Print. Print this term. Download Glossary. English ... Treatment-Experienced. Image(s): (Click to enlarge) Print. Print this term. Download Glossary. English Version PDF(3.13MB) Spanish Version PDF(3.16MB) Connect with us. Facebook.

What is the meaning of drug naive?

Nov 13, 2012 · The outline of treatment designed to remedy a patient's condition is a treatment plan. Treatment plans may encompass curative care or palliative care. Why are estimates useful in patient treatment?

Do treatment-naive patients have more options for antiretroviral therapy?

It's never been treated at all, I'm pretty sure. I guess they don't want any variables in the mix, since treating can lead to some resistance as my hepa explains it. "Is it never having been treated?" Yes that is correct, and no once you tx you will never be tx naive. Hi pcd, in the early stages of trials most only want tx naive people because ...

What are the 3 active antiretrovirals comprised of?

An antiretroviral (ARV) regimen for a treatment-naive patient generally consists of two nucleoside reverse transcriptase inhibitors (NRTIs) administered in combination with a third active ARV drug from one of three drug classes: an integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase ...Jun 3, 2021

What is treatment optimization?

Summary: HIV treatment optimization is a process intended to enhance the long-term efficacy, adherence, tolerability, safety, convenience, and affordability of combination ART. The ultimate goal of this process is to expand access to well tolerated and effective lifetime treatment to all those in need.

What is the best ARV combination?

A triple-drug combination of zidovudine, didanosine and nevirapine has been found to outperform combination therapy with two nucleosides as demonstrated by changes in the viral load and the CD4⁺ count.Jun 1, 1998

What is ARV made of?

The three-in-one pill

The most commonly chosen regimen for treatment is an all-in-one-pill, or fixed dose combination, that contains the antiretroviral drugs tenofovir, emtricitabine and efavirenz.Nov 22, 2016

What is ARV optimization?

Antiretroviral therapy (ART) optimization is the harmonization of global efforts to accelerate access to simpler, safer and more affordable HIV treatment. To meet the needs of people in low- and middle-income countries, HIV treatment must be effective, safe, well-tolerated and affordable.Jul 12, 2021

What are naive patients?

The term naïve patient refers to two specific categories: i) patients with no previous therapeutic exposure to originator (“primary naïve”), and ii) patients with previous exposure to the originator but with a wash-out period of time adequately long based on the judgment of the clinician (“secondary naïve”) [7].

What is the name of the new ARV pill?

Early results from people taking a new antiretroviral medication called lenacapavir are promising. The long-acting drug is still at the research stage, but if the developers are able to pair it effectively with other drugs that also only needs to be taken twice a year, it could revolutionise HIV treatment.Jul 26, 2021

What is antiretroviral naive?

Do ARVs make you gain weight?

Weight gain is a common side effect of antiretroviral therapy (ART). On average, people put on about 4 pounds during the first 2 years of their treatment. Most of that gain happens in the first year.Nov 15, 2021

Does ARVs change body shape?

Lipodystrophy, or “lipo” for short, is a collection of body shape changes in people taking antiretroviral medications (ARVs). “Lipo” refers to fat, and “dystrophy” means bad growth. These changes include fat loss, fat deposits, and metabolic changes. Fat loss occurs in the arms, legs, or face (sunken cheeks).

What Colour are ARVs?

ARVs included green oval tablets (Trizivir), yellow capsules (efavirenz) and round orange-and-white tablets (Lamivir).

Question

I dont seem to understand what is meant by a treatment naive patient. Would like to know if am one of them.

Answer

"Treatment naive" means you have never been treated before with antiretroviral therapy.

GEMINI CLINICAL TRIALS

The clinical trials for DOVATO—GEMINI 1 & 2—were performed at 192 centers in 21 countries. The primary objective of the studies was to evaluate the efficacy and safety of DOVATO, a two-drug regimen, compared with the three-drug regimen of DTG + TDF/FTC for treatment of HIV-1 infection in ART-naïve adults.

TRIAL DESIGN

The proportion of patients with HIV-1 RNA <50 copies/mL at Week 48 using the FDA snapshot analysis with 10% noninferiority margin

EFFICACY

The virologic efficacy of DOVATO has been tested in two Phase 3 clinical trials—GEMINI 1 & 2. Detailed below are primary endpoint results as well as the results from some prespecified secondary endpoints.

GEMINI 1 & 2: 96-Week SUBGROUP ANALYSIS

In patients with no virologic data at Week 96, none had last HIV-1 RNA value >50 copies/mL except for 1 patient in the DTG + TDF/FTC group.

RESISTANCE RESULTS

As a prespecified secondary endpoint, patients who met the protocol-defined confirmed virologic withdrawal criteria across the pooled GEMINI-1 and GEMINI-2 trials were tested for emergent INSTI or NRTI substitutions conferring resistance through 144 weeks.

BONE AND RENAL BIOMARKERS

ADJUSTED MEAN CHANGE FROM BASELINE ( µg /L) THROUGH WEEK 96 (PRESPECIFIED SECONDARY ENDPOINT)**

Treatment FAQ